Skip to main content
. 2023 Sep 28;62(3):2202210. doi: 10.1183/13993003.02210-2022

FIGURE 7.

FIGURE 7

Gene signatures defining how the effects of oxidised interleukin 33 (IL-33ox) in bronchial epithelial air–liquid interface (ALI) cultures correlate with disease severity in patients with chronic obstructive pulmonary disease (COPD). a) Gene set variation analysis (GSVA) of the tozorakimab (tozo) and IL-33ox signatures in the GSE37147 cohort samples. b) GSVA showing the correlation with disease severity in the GSE47460 cohort samples derived from lung explants, as assessed by gene enrichment according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages. c) GSVA showing the correlation of genes downregulated in COPD ALI cultures following IL-33-neutralising antibody (tozorakimab) treatment with disease severity (GOLD1–4) in the GSE47460 cohort samples, as assessed by gene enrichment score according to predicted forced expiratory volume in 1 s (FEV1). d) GSVA showing the correlation with smoking status and COPD in the GSE11784 cohort samples derived from lung explants. Data are plotted as mean±sem. Details of box plots can be found in the supplementary materials. CS: current smoker; EX: ex-smoker; HV: healthy volunteer; NS: non-smoker. *: p≤0.05; **: p≤0.01; ***: p≤0.001; ****: p≤0.0001 (one-way ANOVA with Tukey's honest significant difference test).